Washington University has been a CALGB main member institution since 1986. Over the last six years, the Siteman Cancer Center (SCC) at Barnes-Jewish Hospital and Washington University School of Medicine (WUMS) has grown to become one of the leading NCI Cancer Centers nationally. Designated in 2004 as a Comprehensive Cancer Center and in 2006 as the 20th member of the National Comprehensive Cancer Network (NCCN), Siteman has enhanced its collaborative and translational infrastructure, which has increased the scientific capacity of the CALGB at Washington University. During the last grant cycle, 3 Washington University faculty members chaired CALGB scientific committees, and 11 additional faculty members served on scientific committees. From 2003-2008, WUMS faculty chaired 26 treatment and correlative science protocols and co-authored 74 CALGB publications. WUMS has continued to accrue well throughout the entire grant period, ranking in the top 5 among CALGB institutions every year. WUMS accrual to all CALGB trials during this grant period averaged 293/year with an average of 140 patients/year accrued to therapeutic trials. Our portfolio remains diverse with excellent accruals to breast, Gl, GU, leukemia and lymphoma studies. Several newfaculty recruits in 2007-2008 will further enhance our ability to contribute to the CALGB scientific mission, specifically in the areas of breast cancer, pharmacology and experimental therapeutics, thoracic oncology, leukemia, and lymphoma. Collaborations are ongoing between WUMS investigators and the CALGB leukemia tissue bank, with continued efforts to identify key mutations in AML. Goals for the next grant cycle include 1) continued efforts to increase accruals, particularly minority accruals to CALGB trials, 2) increased involvement of WUMS investigators in CALGB scientific committees specifically leukemia, PET, Gl, and imaging 3) increased involvement of our very experienced and outstanding CRAs in the audit and CRA committees, and 4) improved communication between WUMS and CALGB regarding resources available at the SCC that will enhance the scientific mission of CALGB, specifically our ability to perform high quality correlative studies.

Public Health Relevance

Siteman Cancer Center is the only NCI-designated cancer center in Missouri or southern Illinois and for a 240-mile radius, and it continues to be the leading oncology treatment facility within the St. Louis metropolitan area. Participation in CALGB allows Washington University physicians to offer a broad range of clinical trials to patients with all types and stages of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Kolitz, Jonathan E; George, Stephen L; Benson Jr, Don M et al. (2014) Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 120:1010-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Walker, Alison; Mrozek, Krzysztof; Kohlschmidt, Jessica et al. (2013) New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461. Genes Chromosomes Cancer 52:385-401
Ellis, Matthew J (2013) Mutational analysis of breast cancer: guiding personalized treatments. Breast 22 Suppl 2:S19-21
Schwind, Sebastian; Edwards, Colin G; Nicolet, Deedra et al. (2013) inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood 121:385-91
Graziano, Stephen L; Gu, Lin; Wang, Xiaofei et al. (2010) Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 5:810-7
Stinchcombe, Thomas E; Hodgson, Lydia; Herndon 2nd, James E et al. (2009) Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-25
Alfano, Catherine M; Day, Jeannette M; Katz, Mira L et al. (2009) Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804. Psychooncology 18:128-33
Stone, Richard M; Donohue, Kathleen A; Stock, Wendy et al. (2009) A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 63:859-64
Vokes, Everett E; Herndon 2nd, James E; Kelley, Michael J et al. (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-704